Los Angeles Capital Management LLC trimmed its holdings in shares of Atara Biotherapeutics, Inc. (NASDAQ:ATRA) by 65.8% during the third quarter, according to the company in its most recent Form 13F filing with the SEC. The firm owned 24,491 shares of the biotechnology company’s stock after selling 47,020 shares during the quarter. Los Angeles Capital Management LLC’s holdings in Atara Biotherapeutics were worth $438,000 as of its most recent filing with the SEC.
A number of other hedge funds have also recently added to or reduced their stakes in ATRA. Dark Forest Capital Management LP bought a new position in Atara Biotherapeutics in the 2nd quarter valued at about $117,000. Amundi bought a new position in Atara Biotherapeutics in the 2nd quarter valued at about $185,000. Amalgamated Bank increased its holdings in Atara Biotherapeutics by 17.4% in the 2nd quarter. Amalgamated Bank now owns 11,944 shares of the biotechnology company’s stock valued at $186,000 after buying an additional 1,774 shares during the period. Algert Global LLC bought a new position in Atara Biotherapeutics in the 2nd quarter valued at about $189,000. Finally, Virtu Financial LLC bought a new position in Atara Biotherapeutics in the 2nd quarter valued at about $197,000.
Several research firms have commented on ATRA. JPMorgan Chase & Co. raised their target price on shares of Atara Biotherapeutics from $26.00 to $27.00 and gave the company an “overweight” rating in a report on Monday, January 3rd. HC Wainwright restated a “buy” rating and issued a $31.00 price target on shares of Atara Biotherapeutics in a research note on Friday. Zacks Investment Research downgraded shares of Atara Biotherapeutics from a “buy” rating to a “hold” rating in a research note on Thursday, November 11th. Mizuho initiated coverage on shares of Atara Biotherapeutics in a research note on Wednesday, October 13th. They issued a “buy” rating and a $41.00 price target on the stock. Finally, Stifel Nicolaus reduced their price target on shares of Atara Biotherapeutics from $30.00 to $27.00 and set a “buy” rating on the stock in a research note on Monday, October 4th. One equities research analyst has rated the stock with a hold rating and six have issued a buy rating to the company. According to MarketBeat, Atara Biotherapeutics has an average rating of “Buy” and a consensus target price of $28.33.
NASDAQ:ATRA opened at $16.07 on Friday. The firm’s 50 day simple moving average is $16.80 and its 200 day simple moving average is $15.65. Atara Biotherapeutics, Inc. has a one year low of $11.81 and a one year high of $21.85. The company has a market cap of $1.42 billion, a PE ratio of -4.44 and a beta of 1.87.
Atara Biotherapeutics (NASDAQ:ATRA) last posted its earnings results on Thursday, November 4th. The biotechnology company reported ($0.90) EPS for the quarter, topping the consensus estimate of ($0.92) by $0.02. The business had revenue of $5.37 million for the quarter, compared to analyst estimates of $5.31 million. During the same quarter in the prior year, the business earned ($0.92) earnings per share. On average, equities analysts predict that Atara Biotherapeutics, Inc. will post -3.29 earnings per share for the current fiscal year.
Atara Biotherapeutics Company Profile
Atara Biotherapeutics, Inc is an allogeneic T-cell immunotherapy company, which pioneers the development of transformative therapies for patients with serious diseases including solid tumors, hematologic cancers, and autoimmune diseases. also delivers off-the-shelf treatments to patients with high unmet medical need.
Further Reading: NASDAQ Stock Market Explained
Want to see what other hedge funds are holding ATRA? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Atara Biotherapeutics, Inc. (NASDAQ:ATRA).
Receive News & Ratings for Atara Biotherapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Atara Biotherapeutics and related companies with MarketBeat.com's FREE daily email newsletter.